Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opaganib in COVID-19 Pneumonia
NCT04414618Phase 2Completed
- Sponsor
- RedHill Biopharma
- Start
- Jul 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in COVID-19 pneumonia comparing Opaganib Arm with Placebo Arm (2 arms). Primary endpoint: Measurement of the Change in Oxygen Requirement From Baseline at 14 days. Started Jul 2020; status: completed.
02
Drugs
Opaganib
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04414618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04414618.